biotech · Cholangiocarcinoma · Irritable Bowel Syndrome With Diarrhea · RDHL
RedHill Biopharma
RedHill Biopharma clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 8045 Arco Corporate Drive, Suite 120, Raleigh, NC 27617, US
- Founded
- 2009
- Employees
- 43
- Programs
- 14
- Drugs
- 10
- Patents
- 40
RedHill Biopharma projects
8 ClinicalTrials.gov programs sponsored by RedHill Biopharma.
RedHill Biopharma has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Opaganib
RedHill Biopharma
COVID-19
2 trials -
Part A: Upamostat 200 mg
RedHill Biopharma
Covid19
1 trial -
RHB-102
RedHill Biopharma
Gastroenteritis
1 trial -
RHB-104
RedHill Biopharma
Crohn's Disease
1 trial -
RHB-104-04
RedHill Biopharma
Crohn Disease
1 trial -
RHB-105
RedHill Biopharma
Dyspepsia
1 trial -
RHB-105
RedHill Biopharma
Helicobacter Pylori Infection
1 trial -
RHB-204
RedHill Biopharma
Pulmonary Mycobacterium Avium Complex Infection
1 trial
Frequently asked questions
How many clinical projects does RedHill Biopharma have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.